Andrew B. Wolf, MD

Contact Information

12631 E. 17th Avenue
Mail Stop B185
Aurora, CO 80045

Phone: (303) 724-4328
Fax: (303) 724-0985
andrew.wolf@cuanschutz.edu

Academic Appointments

Assistant Professor 07/2023-Present
Neuroimmunology, Neurohospitalist, and Neuroinfectious Disease Sections
Program Director, Neuroimmunology Fellowship 07/2026-Present
Department of Neurology, University of Colorado School of Medicine, Aurora, CO

Education

Bachelor of Science (Physiology & Behavior) 05/2010
Arizona State University, Tempe, AZ

Master of Science (Neuroscience) 04/2016
Doctor of Medicine (Clinical Medicine) 05/2018
University of Colorado School of Medicine, Aurora, CO

Clinical Training

Preliminary Internal Medicine Internship 06/2018-06/2019
Neurology Residency 07/2019-06/2022
Neurology Chief Residency 07/2021-06/2022
Neuroimmunology Fellowship 07/2022-06/2023
Department of Neurology, University of Colorado School of Medicine, Aurora, CO

Medical Licensure

Colorado Medical Board, Physician Training License #0007057 04/2018-02/2022
Colorado Medical Board, Physician License #0068220 02/2022-Present
Wyoming Board of Medicine, Physician License #TL8245 05/2024-08/2024
Wyoming Board of Medicine, Physician License #17288A 08/2024-Present
Nebraska Board of Medicine and Surgery, Physician License #36915 04/2025-Present
New Mexico Medical Board, Telemedicine Physician License #TM2025-0085 07/2025-Present

Board Certification

Neurology, American Board of Psychiatry and Neurology, Certificate 64702 09/2022-Present

Active Clinical Privileges

Denver Health Medical Center, Denver, CO 07/2022-Present
University of Colorado Hospital, Aurora, CO 07/2022-Present

DAWN Clinic, Aurora, CO 07/2022-Present

Peer-reviewed Articles

1.) Valla J*, Yaari R*, **Wolf AB**, Kusne Y, Beach TG, Roher A, Corneveaux JJ, Huentelman MJ, Caselli RJ, Reiman EM (2010). Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the *APOE* ε4 allele, the major late-onset Alzheimer's susceptibility gene. J Alzheimers Dis, 22: 307-313. DOI 10.3233/JAD-2010-100129. *Contributed equally

2.) **Wolf AB**, Braden BB, Bimonte-Nelson H, Kusne Y, Young N, Engler-Chiurazzi E, Garcia AN, Walker DG, Moses GSD, Tran H, LaFerla FM, Lue L, Emerson Lombardo N, Valla J (2012). Broad-based nutritional supplementation in 3xTG mice corrects mitochondrial function and indicates sex-specificity in response to Alzheimer's intervention. J Alzheimers Dis, 24: 445-460. DOI 10.3233/JAD-2012-120478.

3.) Hardesty DA, **Wolf AB**, Brachman DG, McBride HL, Youssef EF, Nakaji P, Porter RW, Smith KA, Spetzler RF, Sanai N (2013). The impact of adjuvant stereotactic radiosurgery on atypical meningioma recurrence following aggressive microsurgical resection. J Neurosurg, 119: 475-481. DOI 10.3171/2012.12.JNS12414.

4.) **Wolf AB**, Caselli RJ, Reiman EM, Valla J (2013). *APOE* & neuroenergetics: an emerging paradigm in Alzheimer's disease. Neurobiol Aging, 34: 1007-1017. DOI 10.1016/j.neurobiolaging.2012.10.011.

5.) **Wolf AB**, Valla J, Bu G, Kim J, LaDu MJ, Reiman EM, Caselli RJ (2013). Apolipoprotein E as a β-amyloid independent factor in Alzheimer's disease. Alzheimers Res Ther, 5: 38. DOI 10.1186/alzrt204.

6.) Snyder LA, **Wolf AB**, Oppenlander ME, Bina R, Wilson JR, Ashby L, Brachman DG, Coons SW, Spetzler RF, Sanai N (2014). The impact of extent of resection on malignant transformation of pure oligodendrogliomas. J Neurosurg, 120: 309-314. DOI 10.3171/2013.10.JNS13368.

7.) Oppenlander ME, **Wolf AB**, Snyder LA, Bina R, Wilson JR, Coons SW, Nakaji P, Porter RW, Smith KA, Spetzler RF, Sanai N (2014). An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. J Neurosurg, 120: 846-853. DOI 10.3171/2013.12.JNS13184.

8.) **Wolf AB**, Lintz MJ, Costabile JD, Thompson JA, Stubblefield EA, Felsen G (2015). An integrative role for the superior colliculus in selecting targets for movements. J Neurophysiol,114: 2118-2131. DOI 10.1152/jn.00262.2015.

9.) Perkins M, **Wolf AB**, Chavira B, Shonebarger D, Meckel JP, Leung L, Ballina L, Ly S, Jones TB, Vallejo J, Jentarra G, Valla J (2016). Altered energy metabolism pathways in the posterior cingulate in young adult apolipoprotein E ε4 Carriers. J Alzheimers Dis, 53: 95-106. DOI 10.3233/JAD-151205.

10.) Kusne Y*, **Wolf AB***, Townley K, Conway M, Peyman GA (2017). Visual system manifestations of Alzheimer's disease. Acta Ophthalmol, 95: 668-676. DOI 10.1111/aos.13319. *Contributed equally

11.) **Wolf AB** & Felsen G (2019). How public health policy can be informed by neuroscience. Behav Public Policy, 3: 37-46. DOI 10.1017/bpp.2017.9.

12.) **Wolf AB**, Zhovtis Ryerson L, Pandey K, Vollmer T, Corboy JR, Alvarez E (2019). Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord, 36: 101402. DOI 10.1016/j.msard.2019.101402.

13.) **Wolf AB** & Alvarez E (2021). COVID-19 vaccination in patients with multiple sclerosis on disease-modifying therapy. Neurol Clin Pract, 11: 358-361. DOI 10.1212/CPJ.0000000000001088.

14.) **Wolf AB** & Alvarez E (2022). Ublituximab: A novel anti-CD20 therapy for multiple sclerosis. touchREVIEWS in Neurology. 18:117-121. DOI 10.17925/USN.2022.18.2.117.

15.) Shiao JC*, **Wolf AB***, Rabinovitch RA, Smith C, Kleinschmidt-Demasters BK, Ney DE (2022). Long-term control of primary cerebral ALH amyloidoma with focal radiation therapy. Adv Radiat Oncol, 100831. DOI 10.1016/j.adro.2021.100831. *Contributed equally

16.) Shah AA*, **Wolf AB***, Declusin A, Coleman K, Kammeyer R, Khan B, Corboy JR (2022). Challenging cases in neuroimmunology. Semin Neurol. 42: 695-707. DOI 10.1055/s-0042-1760100. *Contributed equally

17.) Vollmer BL*, **Wolf AB***, Silau S, Corboy JR, Alvarez E (2022). Evolution of disease modifying therapy benefits and risks: an argument for de-escalation as a treatment paradigm for patients with multiple sclerosis. Front Neurol, 799138. DOI 10.3389/fneur.2021.799138. *Contributed equally

18.) **Wolf AB**, Palace J, Bennett JL (2023). Emerging principles for treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Curr Treat Options Neuro. 25: 437-453. DOI 10.1007/s11940-023-00776-1.

19.) **Wolf AB**, Money KM, Chandnani A, Daley CL, Griffith DE, Chauhan L, Coffman N, Piquet AL, Tyler KL, Zimmer S, Montague BT, Mann S, Pastula DM (2023). *Mycobacterium abscessus* meningitis associated with stem cell treatment during medical tourism. Emerg Infect Dis. 29: 23-0317. DOI 10.3201/2908.230317.

20.) **Wolf AB** & Corboy JR (2024). Escalation to anti-CD20 treatment for multiple sclerosis following natalizumab-associated progressive multifocal leukoencephalopathy. Neurol Clin Pract. 12: e200330. DOI 10.1212/CPJ.0000000000200330.

21.) Quinn CM*, Rajarajan P*, Gill AJ, Kopinsky H, **Wolf AB**, de Camargo CS, Lamb J, Bacon TE, Murray JC, Probasco JC, Galetta KM, Kantor D, Coyle P, Bhise V, Alvarez E, Conway SE, Bhattacharyya S, Kister I (2024). Neurologic outcomes in people with multiple sclerosis treated with immune checkpoint inhibitors for oncologic indications. Neurology. 10: e210003. DOI 10.1212/WNL.0000000000210003.

22.) Carlson AM*, Sollero CEV*, **Wolf AB**, Sillau S, Schmitt B, Money KM, Nari KV, Piquet AL, Bennett JL (2025). The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population. Ann Clin Transl Neurol, 12: 169-179. DOI 10.1002/acn3.52268. *Contributed Equally

23.) Riberio A, **Wolf AB**, Lescheck EW, Schonberger LW, Abrams JY, Maddox RA, Appleby BS, Glisic K, Carlson AM, Matthews E (2025). Cadaveric human growth hormone-associated Creutzfeldt-Jakob disease a very long latency period. Emerg Inf Dis. 31: 1189-1192. DOI 10.3201/eid3106.241519.

24.) Ardakani RV*, Crane PD*, Pastula DM, Chauhan L, Matthews E, Money KM, Shah A, Piquet AL, Gross RH, Carlson AM, Tyler KL, Corboy JR, Alvarez E, **Wolf AB** (2025). West Nile virus neuroinvasive disease in patients treated with anti-CD20 therapies. Neurol Clin Pract. 15: e200489. DOI 10.1212/CPJ.0000000000200489. *Contributed equally

25.) Azargui S, Xia JL, McClain IJ, Dacey M, **Wolf AB**, Palestine AG, Reddy AK (2025). Multiple sclerosis associated uveitis successfully controlled with ofatumumab. J Ophthalmic Inflamm Infect 15: 84. DOI 10.1186/s12348-025-00543-0

26.) Borko T, Ritchie A, Selva S, Sillau S, Engebretson E, **Wolf AB**, Alvarez E, Gross RH, Gutierrez E, Corboy JR, Silva D, Kammeyer RM, Piquet AL, Vollmer T, Chahin S, Owens G, Bennett JL, Nair K. Establishing demographic based normative values for neurofilament light chain and glial fibrillary acidic protein in serum and plasma samples. Mult Scler J Exp Transl Clin. In press.

Chapters

1.) **Wolf AB**. Clinical trials in multiple sclerosis. MedLink Neurology. Last revised 11/2024.

2.) **Wolf AB**, Chauhan L, Tyler KL, Pastula D. Infectious mimics of autoimmune disease & post-infectious syndromes in the central nervous system**.** In Neuroimmunology: Multiple Sclerosis, Autoimmune Neurology and Related Diseases. Editors Piquet AL & Alvarez E. Springer. In press.

Letters to the Editor

1.) **Wolf AB**, Alvarez E, Corboy JR (2024). Comparative efficacy of disease-modifying treatments for relapsing multiple sclerosis - variations in real-world experience. JAMA Neurol. 81: 87. DOI 10.1001/jamaneurol.2023.4395.

Invited Commentaries

1.) **Wolf AB** & Alvarez E (2026). Do MRI-negative relapses really exist? No. Mult Scler. Online ahead of press. DOI 10.1177/13524585261423015.

Abstracts & Posters

1.) **Wolf AB**, Kusne Y, Valla J, Yaari R, Beach TG, Roher A, Corneveaux JJ, Huentelman MJ, Caselli RJ, Reiman EM. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the common late-onset Alzheimer's disease susceptibility gene. Arizona Alzheimer's Consortium Annual Conference, Glendale, AZ, 05/2009.

2.) Valla J, Braden BB, Lind J, Young N, Engler L, Garcia A, Bowman B, **Wolf AB**, Page K, Kusne Y, Emerson Lombardo N, Bimonte-Nelson H. Comprehensive polynutrient dietary

supplementation improves cognition in 3xTG mice. Society for Neuroscience Annual Meeting, Chicago, IL, 10/2009.

3.) **Wolf AB**, Kusne Y, Valla J, Yaari R, Beach TG, Roher A, Corneveaux JJ, Huentelman MJ, Caselli RJ, Reiman EM. Reduced posterior cingulate mitochondrial activity in expired young adults with the major Alzheimer's disease susceptibility gene. Society for Neuroscience Annual Meeting, Chicago, IL, 10/2009.

4.) Emerson Lombardo N, Valla J, Braden BB, Lind J, Bimonte-Nelson H, Engler L, Garcia A, Young N, Auerbach SH, Bowman B, **Wolf AB**, Page K, Kusne Y, Volicer L. Nutritional supplement combination therapy improves cognition in 3xTG AD mice and will be tested in cognitively normal adults. Alzheimer's Disease International Annual Conference, Thessaloniki, Greece, 03/2010.

5.) **Wolf AB**, Valla J, Braden BB, Young N, Engler L, Garcia A, Bowman B, Kusne Y, Hatch M, Emerson Lombardo N, Bimonte-Nelson H. Polynutrient dietary supplementation corrects brain mitochondrial biomarkers and improves cognition in the 3xTG mouse model of Alzheimer's disease. Arizona Alzheimer's Consortium Annual Conference, Glendale, AZ, 05/2010.

6.) Valla J, **Wolf AB**, Braden BB, Young N, Engler L, Garcia A, Bowman B, Kusne Y, Hatch M, Emerson Lombardo N, Bimonte-Nelson H. Polynutrient dietary supplementation corrects brain mitochondrial biomarkers and improves cognition in the 3xTG mouse model of Alzheimer's disease. International Academy on Nutrition and Aging Annual Meeting, Santa Ana Pueblo, NM, 07/2010.

7.) Snyder LA, **Wolf AB**, Porter RW, Smith KA, Spetzler RF, Sanai N. The impact of the extent of resection on malignant transformation of pure oligodendrogliomas. Arizona Neurosurgical Society Annual Meeting, Marana, AZ, 10/2011.

8.) Oppenlander ME, **Wolf AB**, Porter RW, Nakaji P, Smith KA, Spetzler RF, Sanai N. An extent of resection threshold for recurrent glioblastomas. Society for Neuro-Oncology Annual Scientific Meeting, Garden Grove, CA, 11/2011.

9.) **Wolf AB**, Konkowski N, Henderson LB, Allred R, Valla J. Foundations of Alzheimer's bioenergetic vulnerability in APOE ε4 carriers. International Conference on Brain Energy Metabolism: Bioenergetics of Neurological Disease and Aging, Pacific Grove, CA, 04/2012.

10.) Snyder LA, **Wolf AB**, Porter RW, Smith KA, Spetzler RF, Sanai N. The impact of the extent of resection on malignant transformation of pure oligodendrogliomas. American Association of Neurological Surgeons Annual Scientific Meeting, Miami, FL, 04/2012.

11.) Oppenlander ME, **Wolf AB**, Porter RW, Nakaji P, Smith KA, Spetzler RF, Sanai N. An extent of resection threshold for recurrent glioblastomas. American Association of Neurological Surgeons Annual Scientific Meeting, Miami, FL, 04/2012.

12.) **Wolf AB**, Konkowski N, Henderson L, Allred R, Valla J. Foundations of Alzheimer's bioenergetic vulnerability in APOE ε4 carriers. Arizona Alzheimer's Consortium Annual Conference, Phoenix, AZ, 05/2012.

13.) Henderson LB, Allred R, **Wolf AB**, Alex M, Konkowski N, Valla J. Foundations of Alzheimer's bioenergetic vulnerability in APOE ε4 carriers. American Osteopathic Association Research Conference, San Diego, CA, 10/2012.

14.) **Wolf AB**, Felsen G. The function of GABAergic neurons in the superior colliculus during decision making. University of Colorado Neuroscience Program Annual Research Conference, Estes Park, CO, 11/2015.

15.) Essig J, **Wolf AB**, Felsen G. Functional role of inhibitory superior colliculus neurons in target selection. Society for Neuroscience Annual Meeting, San Diego, CA, 11/2016.

16.) **Wolf AB**, Pratt RW, Crooks K, Borko T, Parra Gonzales J, Vollmer TL, Frazer-Abel A, Alvarez EA. Humoral response to mRNA-based COVID-19 vaccination in patients with multiple sclerosis on anti-CD20 disease modifying therapies. University of Colorado Department of Neurology Annual Research Retreat, Virtual, 06/2021.

17.) **Wolf AB**, Pratt RW, Crooks K, Borko T, Parra Gonzales J, Vollmer TL, Frazer-Abel A, Alvarez EA. Humoral response to mRNA-based COVID-19 vaccination in patients with multiple sclerosis on anti-CD20 disease modifying therapies. American Neurological Association Annual Meeting, Virtual, 10/2021.

18.) **Wolf AB**, Pratt RW, Crooks K, Borko T, Parra Gonzales J, Vollmer TL, Frazer-Abel A, Alvarez EA. Humoral response to mRNA-based COVID-19 vaccination in patients with multiple sclerosis on anti-CD20 disease modifying therapies. ECTRIMS Annual Congress, Virtual, 10/2021.

19.) Crane PD, Ardakani R, Alvarez E, Chauhan L, Matthews E, Shah A, Pastula D, Money K, Piquet A, Tyler K, **Wolf AB**. Neuroinvasive West Nile virus associated with anti-CD20 treatment for CNS inflammatory diseases. ACTRIMS Annual Forum, West Palm Beach, FL. 03/2024.

20.) Rajarajan P, Quinn C, Gill A, Kopinsky H, Bacon T, **Wolf AB**, Murray J, Probasco J, Galetta K, Kantor D, Alvarez E, Coyle P, Conway S, Bhattacharyya S, Kister I. Multi-institutional study of neurologic outcomes in people with multiple sclerosis who are treated with immune checkpoint inhibitors for oncologic indications. American Academy of Neurology Annual Meeting, Denver, CO. 04/2024.

21.) Ardakani R, Schmitt B, Carlson A, **Wolf AB**, Tyler K, Pastula D, Piquet A. JC virus granule cell neuronopathy mimicking paraneoplastic cerebellar degeneration. American Academy of Neurology Annual Meeting, Denver, CO. 04/2024.

22.) Sollero CEV, Money KM, **Wolf AB**, Schmitt B, Sillau S, Nair KV, Piquet AL, Bennett JL, Carlson AM. Epidemiology of seropositive neuromyelitis optica spectrum disorder in a large US population. American Academy of Neurology Annual Meeting, Denver, CO. 04/2024.

23.) Gill A, Quinn C, Rajarajan P, Gill A, Kopinsky H, **Wolf AB**, Bennett JL, Soares de Camargo C, Murray J, Conway S, Alvarez E, Coyle PK, Galetta K, Bhise V, Kantor D, Probasco J, Bhattacharyya S, Kister I. Disease Activity in People Living with MS and NMOSD Exposed to Immune Checkpoint Inhibitors: A Multi-Institutional Study. Consortium of Multiple Sclerosis Centers Annual Meeting, Nashville, TN. 04/2024.

24.) Ardakani R, Schmitt B, Carlson A, **Wolf AB**, Tyler K, Pastula D, Piquet A. JC virus granule cell neuronopathy mimicking paraneoplastic cerebellar degeneration. American Academy of Neurology Summer Conference, Atlanta, GA. 07/2024.

25.) Ardakani R, Crane PD, Alvarez E, Chauhan L, Matthews E, Shah A, Pastula D, Money K, Piquet A, Tyler K, **Wolf AB**. Neuroinvasive West Nile virus associated with anti-CD20 treatments. American Academy of Neurology Summer Conference, Atlanta, GA. 07/2024.

26.) Schmitt B, Sollero CEV, Money KM, **Wolf AB**, Sillau S, Nair KV, Piquet AL, Bennett JL, Carlson AM. Epidemiology of seropositive neuromyelitis optica spectrum disorder in a large US population. American Academy of Neurology Summer Conference, Atlanta, GA. 07/2024.

27.) Doerfler M, Alvarez E, **Wolf AB**. Neutropenia and neutropenic fever in patients with multiple sclerosis on B-cell depleting therapies. American Academy of Neurology Annual Meeting. San Diego, CA. 04/2025.

28.) Doerfler M, Alvarez E, **Wolf AB**. Neutropenia and neutropenic fever in patients with multiple sclerosis on B-cell depleting therapies. Consortium for Multiple Sclerosis Centers Annual Meeting. Phoenix, AZ. 05/2025.

29.) **Wolf AB**, Bosque P, Silau S, Kielty T, Adkisson I, Engebretson E, Valdez C, Geyer M, Lublin A, Chavin J, Nair KV. Bridging the Gap: Engaging non-traditional sites to enhance inclusion in multiple sclerosis clinical research. ACTRIMS Annual Forum. San Diego, CA. 02/2026.

30.) Upchurch M, Doerfler M, **Wolf AB**. Trident sign associated with glial fibrillary acidic protein (GFAP) astrocytopathy. ACTRIMS Annual Forum. San Diego, CA. 02/2026.

31.) Omari M, **Wolf AB**, Alvarez E, Manini L, Corboy J, Kister I. What happens when older multiple sclerosis patients stop their anti-CD20? A two-center retrospective study. American Academy of Neurology Annual Meeting. Chicago, IL 04/2026.

32.) Upchurch M, Doerfler M, **Wolf AB**. Trident sign associated with glial fibrillary acidic protein (GFAP) astrocytopathy. American Academy of Neurology Annual Meeting. Chicago, IL 04/2026.

33.) **Wolf AB**, Bosque P, Silau S, Kielty T, Adkisson I, Engebretson E, Valdez C, Geyer M, Lublin A, Chavin J, Nair KV. Bridging the Gap: Engaging non-traditional sites to enhance inclusion in multiple sclerosis clinical research. American Academy of Neurology Annual Meeting. Chicago, IL 04/2026.

34.) Gill A, Krett J, Quinn C, Rajarajan P, Babcock L, Kaiser A, Morrison A, Pisano T, Paracha A, Dodson C, Kopinsky H, Moninuola I, Alhassan S, Stewart W, Aguilera-Pena M, Ramierz Guerrero S, Modak N, Jean M, Lamb J, Piura Y, Carrier J, Arvas M, Camargo C, Bhise V, Linnoila J, Chaudhry V, Bhattacharyya S, Alvarez E, Kantor D, Nelsion F, Rammohan K, Coyle P, Hemminger L, Baldwin N, Hutton G, Simpson A, Barreras P, Dujmovic Basuroski I, Harrington C, Douglas A, Day G, Kister I, Galetta K, Conway S, Roy S, Gadani S, **Wolf AB**, Probasco J. Multiple sclerosis disease activity is uncommon in individuals with pre-existing multiple sclerosis exposed to immune checkpoint inhibitor therapy. American Academy of Neurology Annual Meeting. Chicago, IL 04/2026.

35.) Suh J, Greer H, Bennett J, Pastula D, **Wolf AB**. Susac syndrome associated with adenovirus infection. American Academy of Neurology Annual Meeting. Chicago, IL 04/2026.

36.) Gill A, Krett J, Li C, Babcock L, Piura Y, Morrison A, Pisano T, Dodson C, Paracha A, Kaiser A, Alhassan S, Modak N, Moninuola I, Jean M, Carrier J, Arvas M, Stewart W, Lamb J, Aguilera-Pena M, Camargo C, Bhise V, Chaudhry V, Linnoila J, Rammohan K, Nelsion F, Bhattacharyya S, O'Hare M, Roda R, Baldwin N, Coyle P, Hemminger L, Simpson A, Barreras P, Dujmovic Basuroski I, Douglas A, Harrington C, Hutton G, Galetta K, Day G, Conway S, Roy S, Gadani S, **Wolf AB**, Probasco J. American Academy of Neurology Annual Meeting. Chicago, IL 04/2026.

37.) Young A, Gallanis M, Zerwic B, Kammeyer R, **Wolf AB**. Chronic encephalitis in two patients with multiple sclerosis receiving B-cell depleting therapy. Consortium for Multiple Sclerosis Centers Annual Meeting. Charlotte, NC. 05/2026.

Certifications

Advanced Cardiac Life Support (ACLS), initial 05/2018
Basic Life Support (BLS), renewed 04/2024
CITI, GCP for Clinical Trials with Investigational Drugs and Medical Devices, renewed 01/2025
CITI, Group 1 Biomedical Investigators, renewed 01/2025
CITI Health Information Privacy and Security (HIPS) for Clinical Investigators, renewed 01/2025
CITI Health Information Privacy and Security (HIPS) for Clinicians, renewed 01/2025
DEA Controlled Substance Registration Certificate, FW1597701, renewed 04/2025
Neurostatus Expanded Disability Status Scale (EDSS), Level C, renewed 03/2025
New Mexico Controlled Substance License, CS02327035, renewed 05/2026
NIH Stroke Scale, renewed 07/2025
Wyoming Controlled Substances Registration, CS06054, renewed 05/2026

Professional Memberships

American Academy of Neurology
American Neurological Association
Americas Committee for Treatment and Research in Multiple Sclerosis
Autoimmune Encephalitis Alliance
Autoimmune Neurology Research Consortium
Colorado Clinical and Translational Sciences Institute
Colorado Neurological Society
Consortium of Multiple Sclerosis Centers
Siegel Rare Neuroimmune Association
White Matter Rounds Network

Journal Review Activity

Acta Neurologica Scandinavia
Acta Ophthalmologica
Brain and Behavior
Clinical Case Reviews
Cureus
Frontiers in Immunology

Frontiers in Neurology
Frontiers in Pharmacology
Journal of Clinical Pharmacy and Therapeutics
Journal of Neurology
Multiple Sclerosis and Related Disorders
Neuroimmunology Reports
Neurology
Neurology Clinical Practice
Neurology Education
Neurotherapeutics
The Neurohospitalist

Clinical Trials (as principal investigator / site principal investigator)

NCT06433752. A study evaluating the real-world experience of participants treated with ublituximab-xiiy for relapsing multiple sclerosis (ENABLE).
Role: Site Principal Investigator
Dates: 2025-Present

NCT06860633. Treatment of myasthenia gravis exacerbation or crisis with efgartigimod: a single arm, open label prospective cohort study.
Role: Principal Investigator
Dates: 2025-present

NCT04047628. Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS).
Role: Site Principal Investigator
Dates: 2026-Present

NCT07477639. Treatment of participants with primary or secondary progressive multiple sclerosis (IMPACT-MS)
Role: Site Principal Investigator
Dates: 2026-Present

NCT06900192. A study of allogeneic hematopoietic cell transplantation for primary progressive multiple sclerosis.
Role: Site Principal Investigator
Dates: In startup

Clinical Trials (as subinvestigator)

NCT03972306. A study to investigate the pharmacokinetics, safety, and tolerability of subcutaneous ocrelizumab administration in participants with multiple sclerosis (OCARINA I).
Dates: 2022-2023

NCT04544449. A study to evaluate the efficacy and safety of fenebrutinib compared with ocrelizumab in adult participants with primary progressive multiple sclerosis (FENtrepid).
Dates: 2022-Present

NCT05503264. A study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in patients with anti-N-methyl-D-aspartic acid receptor (NMDAR) or anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis (CIELO).
Dates: 2024-Present

NCT04586010. A study to evaluate the efficacy and safety of fenebrutinib compared with teriflunomide in relapsing multiple sclerosis (FENhance).
Dates: 2024-Present

NCT06529406. Prospective evaluation of sequencing from anti CD-20 therapies to ozanimod (COAST).
Dates: 2025-Present

NCT05156281. Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis (REMODEL-2).
Dates: 2025-Present

NCT06220201. A study to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with relapsing forms of multiple sclerosis, progressive forms of multiple sclerosis or refractory myasthenia gravis (MG) (Breakfree-2)
Dates: 2025-Present

NCT04548999. A study to evaluate the efficacy, safety and pharmacokinetics (PK) of a higher dose of ocrelizumab in adults with primary progressive multiple sclerosis (PPMS) (GAVOTTE).
Dates: 2025-Present

NCT07100990. Treatment of inflammatory myelitis and optic neuritis with early vs rescue plasma exchange (TIMELY-PLEX).
Dates: 2026-Present

Active Grant Funding

Project: PRE-DISC MRI: PREdicting Relapse Events after Disease-Modifying Therapy (DMT); DISContinuation with Magnetic Resonance Imaging (MRI)
Role: Principal Investigator
Source: Rocky Mountain MS Center
Date: 07/2025
Total Costs: $3,256

Project: Risk factors and longitudinal outcomes for demyelinating diseases associated with TNF-alpha inhibitor use
Role: Principal Investigator
Source: Rocky Mountain MS Center
Date: 07/2025
Total Costs: $5,000

Project: Neuroimmunology patient database development
Role: Co-Principal Investigator
Source: Rocky Mountain MS Center
Date: 07/2026
Total Costs: $25,762

Teaching

University of Colorado Medical Students:

IDPT 5022 Nervous System
Neuropathology Lab – Neuroimmunology, 03/07/2022 (170 students, 4 hours)
Neuropathology Lab – Neuroimmunology, 03/06/2023 (170 students, 2 hours)
Neuropathology Lab – Neuroimmunology, 03/05/2024 (85 students, 2 hours)
Neuropathology Lab – Neuroimmunology, 03/10/2025 (85 students, 2 hours)
Neuropathology Lab – Neuroimmunology, 03/09/2026 (170 students, 4 hours)

IDPT 7041 Neurologic Care
Problem Based Learning – Acute Stroke, 09/03/2020 (12 students, 2 hours)

IDPT 8037 Advanced Neuroscience
Neuropathology Lab – Neuroimmunology, 11/16/2022 (170 students, 4 hours)
Neuroimmunology Cases, 12/15/2022 (170 students, 1 hour)
Neuroinflammation Cases, 10/25/2023 (170 students, 2 hours) w/ Kelli Money, MD/PhD
Neurological Exam Teaching session, 09/22/2024 (10 students, 2 hours)
Neuroinflammation Cases, 09/23/2024 (170 students, 3 hours) w/ Kelli Money, MD/PhD
Neurological Exam Teaching session, 08/21/2025 (10 students, 2 hours)
Neuroinflammation Cases, 09/29/2025 (170 students, 3 hours) w/ Kelli Money, MD/PhD
Neuroinflammation Cases, 09/28/2026 (170 students, 3 hours) w/ Kelli Money, MD/PhD

IDPT 7006 Foothills Basecamp Transition to Clerkships
Oral Presentations, 09/06/2023 (4 students, 2 hours)
Applying EBM: Answering Clinical Questions at the Bedside, 08/31/2026 (12 students, 2 hours)

IDPT 8060 Alpine Basecamp Transition to Advanced Clerkships
Summarizing Evidence in Clinical Presentations, 01/31/2024 (8 students, 2 hours)

University of Colorado Neurology Residents:

Didactic Lectures, ~24 residents, 1 hour
Clinical Anatomy Cases – Spinal Cord, 12/02/2020
Neuroimmunology Board Review, 01/06/2021
Neuroradiology Cases – Neuroimmunology & Neuro-ophthalmology, 01/20/2021
Neuroradiology Cases – Neuroinfectious Disease, 06/16/2021 (w/ Madeline Garza, MD)
Neurological Emergencies in Pregnancy, 08/25/2021 (w/ Sharon Poisson, MD)
Burnout in Neurology: Definitions, Quantification, and Intervention, 9/1/2021
Epilepsy Neuroimaging, 10/27/2021
Epilepsy Clinical Cases, 10/27/2021 (w/ Dave Jeon, MD)
Pediatric Neuroimmunology, 01/12/2022
Neuroimmunology Board Review, 01/19/2022
Neuroradiology Cases – Neurodegenerative Disease, 05/11/2022
Neuro-oncology Board Review, 05/18/2022
Neurological Emergencies in Pregnancy, 08/24/2022 (w/ Sharon Poisson, MD)
Pediatric Neuroimmunology, 11/30/2022
Neurological Emergencies in Pregnancy and the Postpartum Period, 08/23/2023
Neuroradiology: MS, NMOSD, and MOGAD, 11/15/2023 (w/ Justin Honce, MD)
Neurological Emergencies in Pregnancy and the Postpartum Period, 08/07/2024

Leukodystrophies & Misdiagnosis of Acquired Inflammatory Disorders, 01/22/2025
Neuroimmunology Review, 01/29/2025
Acute Neuroimmunology, 08/13/2025
Neurological Emergencies in Pregnancy and the Postpartum Period, 08/20/2025
Neuroimmunology Symptom Management, 02/18/2026
Clinical Trials Concepts, 07/15/2026
Acute Neuroimmunology, 08/12/2026

Team-Based Learning, ~24 residents, 2 hours
Neuroimmunology, 12/05/2023
Neuroimmunology, 01/29/2025
Neuroimmunology, 03/11/2026

Educational Materials

Neurology Residency Survival Guide – Neuroimmunology Chapter, 06/2021 (w/ Anthony Declusin, MD)
Practical Overview of Multiple Sclerosis Diagnosis & Management, revised 04/2026

Mentorship

University of Colorado Neuroimmunology Fellows:
Molly Moehlman, MD 2023-2024 (now at Cincinnati Children's Hospital)
Elle Wade, MD 2024-2025 (now at University of Colorado)
Matthew Doerfler, MD 2024-2025 (now at Children's Hospital Colorado / University of Colorado)
Margaret Upchurch, MD 2025-2026 (now at Intermountain Healthcare)
Amy Young, MD 2025-2026 (now at Denver Health / University of Colorado)
Kyra Curtis, MD 2026-2027
Alexandra Rincones, MD 2026-2027

University of Colorado Neurology Residents:
Austin Browning, MD 2024-Present
Jonas Fast, MD 2024-Present

University of Colorado Medical Students via Developing our Clinical Skills (DOCS):
Hanna Vanderpool, MS1 2023-2024
Sherwin Atighetchi, MS1 2024-2025
Ashley Jung, MS1 2025-2026
Megan Tidd, MS1 2026-2027

University of Colorado MSTP Students via Foundations of Doctoring (FOD):
Courtney Vetter, 2026-Present
Matthew Mardo, 2026-Present

University of Colorado BA/MD Program Students:
Isabel Greenberg, 2026-Present

Boulder Valley School District Science Research Seminar Students:
Samantha Baun 2024-2025 (now undergraduate at Colorado State University)

Clinical Duties

I maintain a subspecialty neuroimmunology clinic with approximately 650 patients on my panel, the majority of whom have multiple sclerosis. I attend approximately 12 weeks per year on the inpatient consult and general neurology services at the University of Colorado Hospital. I also share responsibility for about 200 patients seen at the Denver Health neuroimmunology clinic and serve as an outpatient general neurologist at the DAWN Clinic (free community clinic) one evening per month.

Clinical Supervision

University of Colorado Medical Students:
University of Colorado Hospital neuroimmunology clinic, ~2 half-days monthly, 07/2023-present
DAWN Clinic, ~1 evening monthly, 07/2023-present

University of Colorado Neurology Residents:
Denver Health neuroimmunology clinic, ~6 half-days yearly, 07/2022-present
University of Colorado Hospital continuity clinics, ~6 half-days yearly, 07/2023-07/2024
University of Colorado Hospital neuroimmunology clinic, ~4 half-days monthly, 07/2023-present
DAWN Clinic, ~1 evening monthly, 07/2023-present
University of Colorado Hospital inpatient services, ~10 weeks yearly, 7/2025-present

University of Colorado Neuroimmunology Fellows:
University of Colorado Hospital neuroimmunology clinic, ~6 half-days monthly, 07/2023-present

University of Colorado Neuroinfectious Diseases Fellows:
University of Colorado Hospital neuroimmunology clinic, ~2 half-days monthly, 10/2024-present

University of Colorado Neurohospitalist and Vascular Neurology Fellows:
University of Colorado Hospital inpatient services, ~6 weeks yearly, 07/2025-present

Intramural Presentations

University of Colorado Neurology Grand Rounds:
Clinical Case Review, 04/12/2023 (w/ Anna Shah, MD & Jennifer Simpson, MD)
BTK Inhibitors: The Next Wave in MS Treatment, 04/19/2023 (w/ Anthony Declusin, MD)

University of Colorado Neurology Research Retreat:
Arguments for Disease-modifying Therapy De-escalation in Multiple Sclerosis, 06/01/2022

Extramural Presentations

1.) Acute Management of NMOSD. From Clinical Studies to the Real World: Sharing Clinical Experience in the Treatment of NMOSD. Horizon Therapeutics. Aurora, CO. 11/2023.

2.) Use and Misuse of Stem Cell Treatments and Implications for Medical Tourism. Stem Cell Transplantation in Neurology: the Good, the Bad, and the Ugly. American Academy of Neurology Annual Meeting. Denver, CO. 04/2024.

3.) Metrics of Disability Accrual in Multiple Sclerosis. Multiple Sclerosis Education Day. Novartis. Aurora, CO. 05/2024.

4.) Multiple Sclerosis Therapies. Perspectives of Academic Systems in Providing Neurological Care. AJMC Institute for Value Based Medicine. Aurora, CO. 10/2025.

5.) Beyond DMT Discontinuation: De-escalation Strategies. Disco and Beyond Disco with a Pharmacists' Twist. Consortium of Multiple Sclerosis Centers Annual Meeting. Charlotte, NC. 05/2026.

Intramural Service

University of Colorado Cancer Center:
Member, Cellular Therapies Data Safey Monitoring Committee, 12/2024-Present

University of Colorado Department of Physiology & Biophysics:
Chair, COMIRB 25-1114 Data Safety Monitoring Board, 10/2026-Present

University of Colorado Hospital:
STEWARDS Group (lumbar puncture quality improvement), 7/2026-Present

University of Colorado MD Program:
MD Admissions Interviewer, 2023-2024
BA/BS-MD Admissions Interviewer, 2023-2024
AAN SIGN Career Panel, Aurora, CO, 03/2025
AAN SIGN Career Session, Aurora, CO, 06/2026
AAN SIGN Lumbar Puncture Training, Aurora, CO 09/2026

University of Colorado Neuroimmunology Fellowship:
Associate Program Director, 07/2023-07/2026
Program Director, 07/2026-Present

University of Colorado Neurology Residency Program:
Resident Selection Committee, 07/2022-Present
Director, Didactics Neuroimmunology Block (12 hours of content), 07/2023-Present
Director, Journal Club (monthly 1-hour sessions), 07/2023-Present
Graduate Medical Education Confidential Advisor, 07/2025-Present

Extramural Service

ACTRIMS fellowship webinar series, organizing committee, 2022-2023
American Academy of Neurology, session monitor, Boston, MA, 04/2023
American Academy of Neurology, grant reviewer, 2024-2026
Autoimmune Neurology Research Consortium, Board of Directors, 01/2025-Present
American Academy of Neurology, abstract reviewer, 2026

Clinical Outreach

AHEC health screenings, National Western Stock Show, Denver, CO, volunteer, 01/2016
DAWN Clinic, Aurora, CO, volunteer physician, 05/2022-Present (1 evening monthly)

Educational Outreach

Denver Museum of Nature & Science, Brain Awareness Week, Denver, CO, 03/2016
AHEC, Rio Grande Inn, La Jara, CO, 07/2016
Helmet Heads, Aurora, CO, 05/2017
Rocky Mountain MS Center, Conversations on MS, Pueblo, CO, 10/2023
National MS Society, ECHO MS, Mountain Hub, 2023-2024
Rocky Mountain MS Center, Spring Education Summit, 04/2024
Rocky Mountain MS Center, Conversations on MS, Broomfield, CO, 09/2024
Rocky Mountain MS Center, Use and Misuse of Stem Cell Treatments (webinar), 10/2024
Rocky Mountain MS Center, Virtual Rural Engagement Program, Farmington, NM, 10/2024
Rocky Mountain MS Center, Rural Engagement Program, Farmington, NM, 05/2025
Rocky Mountain MS Center, Conversations on MS, Durango, CO, 05/2025
Rocky Mountain MS Center, Conversations on MS, Grand Junction, CO, 07/2025
Rocky Mountain MS Center, Sleep and Multiple Sclerosis (webinar), 08/2025
Rocky Mountain MS Center, Fall Education Summit, 11/2025
Rocky Mountain MS Center, Conversations on MS, Cheyenne, WY, 06/2026
Rocky Mountain MS Center, Conversations on MS, Durango, CO, 10/2026

Media

1.) VJ Neurology. Raising awareness of the misuse of stem cell therapies in neurology. 04/2024. https://www.vjneurology.com/video/cqbbxwldjr8-raising-awareness-of-the-misuse-of-stem-cell-therapies-in-neurology/

2.) VJ Neurology. Exploring the use of stem cell therapies for patients with MS. 04/2024. https://www.vjneurology.com/video/nyea2d2le1i-exploring-the-use-of-stem-cell-therapies-for-patients-with-ms/

3.) FOX31 KDVR Denver. Doctors explain health conditions that lead to severe illness from West Nile virus. 07/2025. https://kdvr.com/news/local/doctors-explain-health-conditions-that-lead-to-severe-illness-from-west-nile-virus/

4.) ABC7 KMGH Denver. West Nile virus: Health experts urge precautions in Colorado. 08/2025. https://www.denver7.com/news/local-news/west-nile-virus-health-experts-urge-precautions-in-colorado

5.) AJMC. Overcoming access, cost barriers in MS. 10/2025. https://www.ajmc.com/view/overcoming-access-cost-barriers-in-ms-andrew-wolf-md

6.) Everyday Health. Can Vitamin D Help with Multiple Sclerosis Management? 11/2025. https://www.everydayhealth.com/columns/trevis-gleason-life-with-multiple-sclerosis/apparently-conflicting-information-about-vitamin-d/

7.) Everyday Health. How to Maintain a Healthy Weight When You Have Multiple Sclerosis. 09/2026. https://www.everydayhealth.com/neurological-disorders/multiple-sclerosis-weight-management/

8.) Everyday Health. Types of Incontinence Pads for MS and How They Differ. 10/2026. https://www.everydayhealth.com/neurological-disorders/types-of-incontinence-pads-for-ms/


Honors

Summa cum laude, Arizona State University, 05/2010
Extra Mile Award, University of Colorado Neurology Residency Program, 06/2022
Resident Research Award, University of Colorado Neurology Residency Program, 06/2022
Al Anderson Teaching Award, University of Colorado Neurology Residency Program, 06/2024
Medical Student Teaching Award, University of Colorado Department of Neurology, 06/2025

Financial Disclosures

Grant support from Alexion, Argenx, the Brotherton Foundation, the Rocky Mountain MS Center, and Sanofi; site investigator for clinical trials sponsored by Biogen, Bristol Myers Squibb, Genentech, the Immune Tolerance Network, the Michael J. Fox Foundation, Novartis, PCORI, and TG Therapeutics; consultant for Orca Bio; honoraria from the Consortium for Multiple Sclerosis Centers, the Institute for Value-Based Medicine, and the Rocky Mountain MS Center; travel support from the Consortium for Multiple Sclerosis Centers, the Rocky Mountain MS Center, and Tr1X Bio; non-compensated relationship as a member of the Board of Directors of the Autoimmune Neurology Research Consortium, Inc.

Additional information at https://openpaymentsdata.cms.gov/physician/11313629



15 November 2026